Baker M A, Taub R N
Oncology. 1978;35(5):214-6. doi: 10.1159/000225289.
Three preparations of BCG, currently in use for clinical trials in cancer, were tested for relative potency as an immunological adjuvant. Using a lymphocyte trapping assay, Pasteur Institute BCG was shown to be a more effective adjuvant than the Tice strain or the Glaxo preparation of BCG.
目前用于癌症临床试验的三种卡介苗制剂，作为免疫佐剂进行了相对效力测试。使用淋巴细胞捕获试验表明，巴斯德研究所的卡介苗比蒂氏菌株或葛兰素公司生产的卡介苗制剂是更有效的佐剂。
